Unwrapping DIY enquiry: The study of 'enquiry' in DIY practice at individual, community & place levels

Do-It-Yourself (DIY) enquiry represents ownership over learning and action: figuring things out by oneself, experimenting, and questioning the state of things to find potential solutions to local concerns. It is an identifiable collective behaviour of self-reliance exhibited throughout our history but in the digital age and in societies with increasing levels of education, the way DIY practice unfolds is little understood. Traditional studies on public engagement in science and technology and perspectives on production of knowledge and technology have focused primarily on institutionally mediated methods of public participation and the validity of public contributions to established fields. This thesis research makes empirical, theoretical, and methodological contributions: using a multi-method approach and grounded theory for qualitative data analysis to explore DIY enquiry in practice, community, and place. The three in-depth case studies explore the nature of the production of knowledge, the role of technologies, and the barriers and opportunities to public engagement in DIY enquiry. Participant observation of a community of DIY practice reveals its inner processes, interactions, and framings of science and technology and how DIY practice is performed through DIY tool use and development. The design and facilitation of a DIY workshop series demonstrates the initial stages of engagement in DIY enquiry and reveals that barriers and opportunities to engagement are mediated by frame of mind, setting, facilitation, and interactions. The observation of place-based citizen initiatives of DIY enquiry reveals its range of interconnected actions: development of techniques and strategies for tool development, data interpretation, and leveraging of knowledge and stance for advocacy. Together the cases reveal the transformative power of DIY enquiry, how it builds knowledge, culture, and identity and that engagement requires curiosity, courage, commitment, and foundational competencies. They also reveal an inherent tension between DIY enquiry framed as a means (seeking collective/organised actionable goals) and as an end (enabling personal empowerment). This research facilitates a better understanding of the democratic potential of public engagement in science in our time but it also promotes the leveraging of knowledge production between professional/institutional science and civil society

Conflictos socioambientales y alternativas de la sociedad civil

Los conflictos socioambientales se multiplican en todo el mundo. Giran en torno a la contaminación industrial, las actividades mineras, el cambio de uso de suelo, la deforestación, la construcción de presas, la introducción de semillas genéticamente modificadas, el mal manejo de desechos sólidos y la privatización de tierra, agua y biodiversidad, entre otros. ¿Cuáles son las causas subyacentes a estos conflictos? ¿Quiénes son los protagonistas? ¿Cuáles son sus demandas, propuestas y estrategias? ¿En qué medida han contribuido a proteger o sanear el medio ambiente? ¿Hay conflictos locales que se convierten en glocales con la intervención de la sociedad civil? Estas interrogantes se abordan en este libro, que recoge inventarios de conflictos ambientales en México, en especial en Jalisco.ITESO, A.C

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk